Isocitrate dehydrogenase mutations as potential tumour agnostic targets

Area of Science:

• Biochemistry
• Oncology
• Epigenetics

Background:

• Isocitrate dehydrogenase (IDH) enzymes are crucial for cellular metabolism and epigenetic regulation.
• Mutations in IDH (mIDH) lead to the production of the oncometabolite 2-hydroxyglutarate (2-HG).
• 2-HG disrupts normal cellular functions, including DNA demethylation, promoting tumorigenesis.

Purpose of the Study:

• To discuss the role and importance of mIDH genes in various cancers.
• To highlight the distinct biological effects of mIDH in different cancer types.
• To emphasize the need for targeted therapies for mIDH-driven cancers.

Main Methods:

• Review of scientific literature on IDH mutations and their role in cancer.
• Analysis of the biochemical pathways affected by 2-HG.
• Examination of the prevalence and prognostic significance of mIDH in different malignancies.

Main Results:

• mIDH mutations are associated with specific cancers like glioma, cholangiocarcinoma, AML, and chondrosarcoma.
• 2-HG accumulation drives hypermethylation, inhibits differentiation, and promotes tumor cell proliferation.
• The impact of mIDH varies across cancer types, with glioma showing distinct prognostic significance.

Conclusions:

• mIDH genes are significant drivers of tumorigenesis through metabolic and epigenetic alterations.
• Understanding the tissue-specific effects of mIDH is crucial for developing effective treatments.
• Targeting mIDH1/2 mutations presents a therapeutic opportunity, but effective treatments are currently limited.